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ABSTRACT
INTRODUCTION
Actinic cheilitis (AC), also called actinic cheilosis 
or solar cheilitis, is a potentially malignant condition 
of the lip vermillion caused by long-time exposure 
to ultraviolet light. This lesion affects mostly the 
lower lip and is more frequent in individuals with 
fair skin, males and those who are regularly in the 
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south region of Brazil, due to the tropical climate 
and the European descent of large part of the 
population, this lesion assumes great importance.
There are two clinical forms of AC: acute 
and chronic. The acute form is more common 
in young individuals and occurs after excessive 
exposure to the ultraviolet light, while the chronic 
form is a cumulative and irreversible alteration. 
In chronic AC, the lip appears parched and 
atrophic, with dyschromic areas, white or gray 
plaques and recurrent erosions7,20. The lesion is 
usually asymptomatic, but can in some cases be 
accompanied by a burning sensation, numbness 
and pain.
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Objective: Actinic cheilitis (AC) is a precancerous lesion of the lip vermillion caused by prolonged exposure to ultraviolet light. The aim of this study was to evaluate the effect 
of 3% diclofenac in 2.5% hyaluronic acid gel in the treatment of AC. Methods: Thirty-four 
patients with chronic AC were treated twice a day with topical diclofenac during a period 
of 30 to 180 days. The individuals were followed up every 15 days by means of clinical 
examination and digital photographic documentation. Results: Of the 27 patients that 
completed the study, 12 (44%) showed complete remission of the whitish plaques and 
exfoliative areas, and 15 (56%) had partial remission of the clinical picture of cheilitis. 
The latter group was submitted to excision of the leukoplakic areas which diagnosis varied 
from mild to moderate epithelial dysplasia. Conclusions: The results suggest a promising 
role for diclofenac in hyaluronic acid gel in the treatment of AC. This treatment has the 
advantages of not being invasive and showing few side effects.
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 The main objectives of treatment of chronic 
AC are to prevent the development of squamous 
cell carcinoma, improve the aesthetic picture 
and diminish the inconvenience caused by 
lip erosions, crusts and roughness. There are 
various therapeutic modalities with the aim of 
removing the altered epithelium of these lesions 
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trichloroacetic acid, imiquimod and retinoids. 
Other treatments include surgical excision with 
cold scalpel (vermillionectomy), vaporization with 
CO2 or Er:YAG laser, cryosurgery, electrodissection 
and photodynamic therapy with aminolevulinic 
acid1,11,15,16. These treatments are very destructive 
and frequently cause considerable discomfort to the 
patients, which has stimulated the development of 
effective and economically viable alternatives for 
the treatment of AC. Diclofenac in hyaluronic acid 
gel has been employed in the topical treatment 
of actinic keratoses with satisfactory results and 
well-tolerated side effects by the majority of the 
patients12,14,19. The present study was conducted 
with the aim of evaluating by means of a clinical 
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follow-up the effect of 3% diclofenac in 2.5% 
hyaluronic acid gel in the treatment chronic actinic 
cheilitis.
MATERIAL AND METHODS
This study was approved by the Research Ethics 
Committee of the Dental School of the Federal 
University of Pelotas, Brazil. Thirty-four patients who 
had been diagnosed with chronic actinic cheilitis, 
seen at the Center for Diagnosis of Oral Diseases 
of the Federal University of Pelotas, Brazil, without 
noteworthy systemic alterations, were enrolled 
for this study. The patients exhibited on physical 
examination areas of leukoplakia (whitish plaques), 
spotting and/or exfoliation of the lip vermillion. The 
inclusion criteria were: presence of white plaques, 
dyschromic and or exfoliative areas in the lower 
lip. Patients with erosion, ulcerated areas and 
plaques with irregular surface were not included 
in the study (exclusion criteria). The objectives of 
the study were explained to the individuals, and 
afterwards, they signed an informed consent form. 
The patients were then submitted to anamnesis 
and physical oral examination. Digital photographic 
documentation was taken for each case to record 
the extent of labial alterations. These alterations 
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areas; Grade II: presence of exfoliative areas; 
Grade III: presence of whitish plaque(s); and 
Grade IV: combination of two or more of these 
alterations.
The treatment protocol consisted of the topical 
application of 3% diclofenac in 2.5% hyaluronic 
acid gel on the lip vermillion, twice a day (morning 
and night), after oral hygiene. The patients were 
instructed to not eat or drink for one hour after the 
application and to use lip sunscreen with SPF 15 
during all day long. The individuals were followed 
up every 15 days, and the period of treatment was 
determined by the response and necessity of each 
case, ranging from 30 to 180 days.
An image record was taken at the initial 
visit and each follow-up visit to evaluate the 
results. The evaluation was performed by two 
calibrated examiners on the basis of information 
of the patient’s chart, physical examination and 
observation of the photographic documentation.
RESULTS
Twenty-seven patients completed the 
treatment. All the subjects were Caucasian, 
with a predominance of fair skin, and most of 
them practiced professional activities involving 
ultraviolet light exposure. The lesion was more 
common among men, with a gender ratio of 8:1 and 
mean age of 58 (SD±12) years old. The patients 
were asymptomatic, although seven individuals 
complained about aesthetic discomfort.
Figure 4 presents the result obtained in 
each case, the grade of actinic cheilitis of the 
patients treated and the duration of the therapy. 
Approximately 78% of the patients exhibited 
Figure 2- Actinic cheilitis grade IV with leukoplakic and spotting areas (a). Lesion showed total remission of the leukoplakic 
area, however, spotting areas continued to be present (b)
Figure 1- Actinic cheilitis grade II, lower lip showed exfoliative areas (a), which exhibited total remission (b) after 60 days 
of topical application of diclofenac
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and 7% grade II. In 48% of the cases, all of the 
extent of the lower lip appeared affected. In the 
other cases, the areas affected varied in extension 
and continuity. The presence of whitish plaques was 
evident in 25 patients, while 23 showed exfoliative 
areas and 24 spotting of the lip.
Improvement of the lesions was observed in 
all the patients, with diminution of the thickness 
of the leukoplakic areas, disappearance of scaling 
areas and greater hydration, besides more uniform 
coloration. Of the 27 patients who completed the 
study, 12 (44%) showed total remission of the 
plaque and exfoliative areas present at the start 
of treatment (Figures 1A, 1B, 2A, 2B). However, 
dyschromic regions continued to be present. Fifteen 
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of AC but without complete resolution of the 
condition (Figures 3A, 3B), with the persistence 
of whitish plaques, which were later excised. The 
diagnosis of these biopsied lesions varied from mild 
to moderate epithelial dysplasia.
The drug utilized was well tolerated by 
the patients, but in two cases, treatment was 
discontinued due to the development of an allergic 
picture characterized by edema and intense 
erythema, associated with a burning sensation 
at the site of drug application. Five patients 
discontinued treatment for personal reasons 
unrelated to the study. All the individuals who 
concluded the study remained on follow-up for at 
least 1 year and routinely used lip sunscreen.
DISCUSSION
Actinic cheilitis is a lesion of the lip vermillion, 
analogous to actinic keratoses, which has been 
treated by surgical procedures and topical drugs, 
some with a cytotoxic effect and the potential to 
cause tissue destruction1,11,16. The topical action 
of diclofenac in a hyaluronic acid vehicle has been 
investigated for the treatment of actinic keratoses, 
showing promising results and less intense adverse 
effects in comparison with other drugs such as 
		17. In the present study, the action 
of diclofenac was investigated in the treatment of 
chronic actinic cheilitis, which showed leukoplakic, 
dyschromic and exfoliative areas. Complete or 
partial remission of the clinical picture of the 
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that corroborates with the studies of Ulrich, et al.18 
(2007) and Nelson, et al.10 (2007), who also utilized 
diclofenac in the treatment of AC, in samples of 
six and 19 individuals, respectively. Ulrich, et al.18 
(2007) utilized this drug for 6 weeks and Nelson, et 
al.10 (2007) for 90 days.
In the present study, the period of treatment was 
Figure 3- Actinic cheilitis grade IV, before (a) and after (b) 180 days of diclofenac topical application. Lip showed partial 
remission of cheilitis, with decrease of the thickness of the leukoplakic areas. The whitish plaque (arrow) was later excised
Figure 4- Gender, age and grade of actinic cheilitis of 
the 27 patients who completed the therapy, as well as, 
period and results obtained with the topical application of 
diclofenac
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based on the clinical response of each case, where 
the maximum period was established as 180 days. 
The complete resolution of the clinical presentation 
determined the suspension of the therapy and was 
obtained in as little as 30 days of treatment. The 
variation in the speed of response to diclofenac 
was also observed in the topical treatment of solar 
keratoses4,13,14,19 and is associated mainly with 
inherent factors of individuals. Additionally, the 
response to treatment depends on the disposition 
and motivation of the patients to achieve a positive 
outcome, as well as the amount of medication 
used in each application. In the present study, the 
amount of substance applied varied based on the 
interpretation by the individuals of the instructions 
supplied by the investigator.
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agent (NSAID) whose mechanism of action is not 
completely understood. Its possible antineoplasic 
effect is being investigated, because it induces 
apoptosis by inhibiting cyclooxygenases (COX-1 
and COX-2), which are involved in the metabolism 
of arachidonic acid and are superexpressed in 
various epithelial tumors3. The hypothesis proposed 
is that NSAIDs, by inhibiting the metabolism of 
arachidonic acid, impede the potent tumorigenic 
effects of its metabolites. Such effects include 
the conversion of pro-oncogenes to oncogenes, 
inhibition of immunologic vigilance, inhibition 
of apoptosis, stimulation of angiogenesis and 
increase in invasiveness of tumor cells8. Therefore, 
diclofenac can be effective in the treatment as well 
as the prevention of epithelial lesions related to 
actinic radiation. 
Hyaluronic acid, the vehicle in which diclofenac is 
delivered, has been widely utilized in the cosmetics 
industry because of its moisturizing properties. 
This polysaccharide was chosen primarily with the 
aim of allowing the accumulation of diclofenac in 
the epidermis, prolonging its half-life at the site of 
action2,9. In addition to these effects, Wolf, et al.19 
(2001) suggested that the hyaluronic acid gel may 
<	<	
treatment.
The lip vermilion is an anatomic site in which 
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permanent scars and susceptibility to irritation10. 
However, the application of diclofenac in hyaluronic 
acid gel did not cause the development of erosive or 
ulcerated areas on the lips. Of the 29 patients who 
effectively underwent treatment, only two showed 
adverse effects that determined their exclusion 
from the study. These local reactions including 
pruritis, erythema and/or burning sensation were 
observed in some cases, and were tolerated by the 
patients. These adverse reactions have also been 
described by other authors who studied the use of 
diclofenac for the treatment of keratoses as well as 
actinic cheilitis10,14,18.
The risk of relapse after the treatment instituted 
is unknown. However, the patients in this study 
were followed-up for more than a year and those 
who had a complete remission of the clinical 
picture of cheilitis showed no signs of recurrence. 
The patients who had a partial remission were 
submitted to excisional biopsy of the whitish 
plaques and displayed no signs of progression of 
the lesion. Meanwhile, the majority of the patients 
studied continue to be exposed to ultraviolet light, 
since they maintained their outdoor occupational 
activities. The follow-up of these individuals and 
their awareness with respect to precautions and 
preventive measures with the use of sunscreen 
and hats are essential.
The results of the present study are in 
accordance with the literature regarding the 
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actinic cheilitis6,7,10. For didactic purposes, in this 
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as grade I through grade IV. Twenty-one out the 
27 patients who were treated showed chronic AC 
grade IV. However, due to the small number of 
patients with cheilitis grade II and III, it was not 
possible to carry out statistical comparisons of the 
results obtained for the different lesion grades.
CONCLUSION
As with the treatment of actinic keratoses, 3% 
diclofenac in 2.5% hyaluronic acid gel showed 
promising results and good tolerability in the 
treatment of AC, indicating a treatment modality 
adequate for this precursor lesion. In addition, 
this treatment has the advantages of not being 
invasive, having low cost and showing few side 
effects and good aesthetic results. There is a need 
for randomized studies to investigate the action 
of this drug; however, as AC is a precancerous 
lesion, the comparison of the action of diclofenac 
in placebo-controlled studies is impracticable. All 
the other available treatment modalities that are 
established for this disease show a high potential 
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compare their effects with those of diclofenac in 
hyaluronic acid gel in randomized clinical trials.
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